The Codex of Legacy: A Note on Endogenic Medicine in the Pre-Pharmacology Era
Before the pharmaceutical industry existed, the practitioners who understood the body best worked with the body's own regulatory chemistry. A short reading of where the bioregulator tradition comes from.
The word pharmacology came into formal English usage in the early nineteenth century. The discipline it describes — the systematic study of how chemical substances exert effects on living organisms — is roughly two hundred years old. The practice it eventually displaced is roughly as old as recorded medicine itself.
What we now call traditional medicine, across most of its long history, was not principally concerned with introducing foreign chemistry to the body. It was concerned with reading what the body was already doing — and assisting it. The herbal pharmacopoeias of ancient China, the formulary lineage of Persian and Arabic medicine, the European herbalism that survived into the nineteenth century, the Andean and West African botanical traditions: these systems differ in detail, but they share a common orientation. The compound is offered as a signal to the body's own regulatory systems, not as a substitute for them.
The pre-pharmacology stance
We use the term endogenic to describe this orientation — working with what arises from within. It is contrasted, not opposed, to the exogenic stance of modern pharmacology, which introduces compounds the body does not produce in order to override pathways the body cannot self-correct. Both stances have their proper place. The endogenic stance has dominated the long arc of human medicine. The exogenic stance has dominated the last two hundred years.
The recovery of the endogenic stance, in a form compatible with twenty-first-century evidence standards, is the project that bioregulator research undertakes. The compounds at the centre of that research — short-chain regulatory peptides — are not new substances. They are short fragments of the body's own signalling chemistry, characterised carefully enough to be studied, formulated, and delivered. The methodology is contemporary. The orientation is ancient.
What was preserved, and what was lost
Two things were preserved in the long tradition that the pharmacology era never fully replaced. The first is the recognition that organ systems possess their own regulatory tone — that the kidney, the liver, the immune compartments, and the skin are not passive substrates but active participants in their own maintenance. The second is the recognition that interventions which support that tone behave differently from interventions which override it. The pharmacology era was less interested in either of these recognitions and built its successes elsewhere.
What was lost, by and large, was the vocabulary. The long tradition spoke in metaphor, in elemental schema, in seasonal correspondences. The vocabulary did not survive contact with twentieth-century science and mostly should not have. But the underlying observations — that the body has regulatory tone, that it can be supported rather than overridden, that compounds derived from the body's own chemistry behave differently from compounds introduced against it — those observations were not wrong. They were waiting for instrumentation that could detect them on their own terms.
“The endogenic stance has dominated the long arc of human medicine. The exogenic stance has dominated the last two hundred years. Both have their proper place.”
Why this matters now
The bioregulator research lineage that this project draws on — four decades of peer-reviewed work centred at the Saint Petersburg Institute of Bioregulation and now distributed across collaborating institutions worldwide — is the first sustained scientific programme to take the endogenic stance seriously on its own terms. The compounds it characterises are short. The mechanisms it proposes are conservative. The clinical data it has generated is now substantial enough to support translation into consumer-facing products subject to the same evidence discipline as any other supplement category.
The category that will eventually carry these compounds into consumer hands — the optimized nutraceutical category, which we have named Opticeuticals — is itself a recovery, not an invention. It recovers the discipline of working with the body's own regulatory systems. It carries it forward under twenty-first-century evidence standards. It is, in that sense, a codex of legacy rendered into modern formulation.
The full institutional treatment of endogenic medicine as a discipline, including the historical lineage and the contemporary research synthesis, is documented at endogenicpharmacology.com. This note serves as an orientation to the longer reading.